Search results for "tetanus toxoid"

showing 10 items of 26 documents

Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.

2018

Abstract Preventive vaccination against tumor-associated endogenous antigens is considered to be an attractive strategy for the induction of a curative immune response concomitant with a long-lasting immunologic memory. The mucin MUC1 is a promising tumor antigen, as its tumor-associated form differs from the glycoprotein form expressed on healthy cells. Due to aberrant glycosylation in tumor cells, the specific peptide epitopes in its backbone are accessible and can be bound by antibodies induced by vaccination. Breast cancer patients develop per se only low levels of T cells and antibodies recognizing tumor-associated MUC1, and clinical trials with tumor-associated MUC1 yielded unsatisfac…

0301 basic medicineCancer ResearchImmunologyMice TransgenicTriple Negative Breast NeoplasmsCancer Vaccines03 medical and health sciences0302 clinical medicineImmune systemAntigenCell Line TumorTetanus ToxoidMedicineAnimalsHumansskin and connective tissue diseasesMUC1Vaccines Syntheticbiologybusiness.industryMucin-1ToxoidGlycopeptidesAntibodies MonoclonalMammary Neoplasms ExperimentalMiddle AgedTumor antigen030104 developmental biologyImmunizationTumor progression030220 oncology & carcinogenesisImmunoglobulin Gbiology.proteinCancer researchFemaleAntibodybusinessCancer immunology research
researchProduct

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers …

2018

To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with…

0301 basic medicineMicrobiology (medical)MalePediatricsmedicine.medical_specialty030106 microbiologyImmunization SecondaryBooster doseAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccines03 medical and health sciences0302 clinical medicineImmunogenicity VaccineSuspensionsGermanyTetanus ToxoidMedicineHumansHepatitis B Vaccines030212 general & internal medicineVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesImmunization ScheduleCzech RepublicHaemophilus VaccinesBooster (rocketry)business.industryDiphtheriaImmunogenicityVaccinationInfant NewbornInfantmedicine.diseaseRotavirus vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesPneumococcal vaccinePediatrics Perinatology and Child HealthFemalebusinessThe Pediatric infectious disease journal
researchProduct

Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.

2017

Breaking tolerance is crucial for effective tumor immunotherapy. We showed that vaccines containing tumor-associated human MUC1 glycopeptides induce strong humoral antitumor responses in mice. The question remained whether such vaccines work in humans, in systems where huMUC1 is a self-antigen. To clarify the question, mice transgenic in expressing huMUC1, mimicking the self-tolerant environment, and wild-type mice were vaccinated with a synthetic vaccine. This vaccine comprised STn and Tn antigens bound to a MUC1 tandem repeat peptide coupled to tetanus toxoid. The vaccine induced strong immune responses in wild-type and huMUC1-transgenic mice without auto-aggressive side effects. All anti…

0301 basic medicineSynthetic vaccinemedicine.medical_treatmentBreast NeoplasmsMice TransgenicBiology01 natural sciencesBiochemistryCancer Vaccines03 medical and health sciencesImmune systemAntigenCancer immunotherapyDrug DiscoverymedicineTetanus ToxoidAnimalsHumansAntigens Tumor-Associated CarbohydrateGeneral Pharmacology Toxicology and PharmaceuticsPharmacologyVaccines Synthetic010405 organic chemistryTetanusOrganic ChemistryMucin-1ToxoidImmunotherapymedicine.diseaseVirologyPeptide Fragments0104 chemical sciencesMice Inbred C57BL030104 developmental biologyImmunizationImmunologyMCF-7 CellsMolecular MedicineFemaleImmunizationChemMedChem
researchProduct

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some M…

1999

Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tetanus toxoid or tuberculin. 11 far advanced stage IV melanoma patients, who were progressive despite standard chemotherapy, received five DC vaccinations at 14-d intervals. The first three vaccinations were administered into the skin, 3 × 106 DCs each subcutaneously and intradermally, followed by two intravenous injections of 6 × 106 and 12 × 106 DCs, respectively. Only minor (less than or equal to grade II) side effects were observed. Immunity t…

AdultMaleLung NeoplasmsImmunologyCD8-Positive T-LymphocytesTuberculincytotoxic T lymphocytesCancer VaccinesMonocytesLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens NeoplasmTetanus ToxoidmelanomaHumansImmunology and AllergyMedicineCytotoxic T celldendritic cellsNeoplasm MetastasisLymph nodeImmunization ScheduleAgedNeoplasm Stagingactive immunotherapybusiness.industryMelanomaDendritic cellMiddle Agedvaccinationmedicine.diseaseTumor antigenNeoplasm Proteinsmedicine.anatomical_structureImmunologyFemaleOriginal ArticlebusinessCD8T-Lymphocytes CytotoxicJournal of Experimental Medicine
researchProduct

A case of agammaglobulinemia characterized by a defect of B-lymphocyte-differentiation to plasma cells

1974

Humoral and cell-mediated immune reactions of a 36-year old patient with a late onset of an agammaglobulinaemia and of his immediate relatives have been investigated. The immunoglobulins gamma-G, gamma-A, gamma-M, gamma-E and gamma-D, and plasma cells in the bone marrow could not be detected in the patient's serum. Immune reactions with PPD and tetanus toxoid as well as the stimulation of the lymphocytes with PHA indicate that the T-cell system was intact. The examination of the peripheral blood lymphocytes by immunofluorescence techniques gave a normal number of B-lymphocytes. These findings could be corroborated by the results of lymphocyte stimulations with anti-IgG. The data suggest tha…

AdultMaleLymphocytePlasma CellsFluorescent Antibody TechniqueImmunoglobulinsStimulationLymphocyte ActivationImmunofluorescenceAgammaglobulinemiaBone MarrowLectinsDrug DiscoveryTetanus ToxoidmedicineHumansHypersensitivity DelayedChildGenetics (clinical)SkinB-Lymphocytesbiologymedicine.diagnostic_testTuberculin TestTetanusToxoidCell DifferentiationImmunoglobulin DGeneral Medicinemedicine.diseaseImmunoglobulin AB-1 cellmedicine.anatomical_structureImmunoglobulin MImmunoglobulin GImmunologybiology.proteinMolecular MedicineBone marrowAntibodyKlinische Wochenschrift
researchProduct

Immunity to tetanus in the 3-20 year age group in Italy

1997

In Italy, systematic mandatory tetanus immunization of children started in 1968. In 1989, immunity against tetanus was assessed in a random sample of 758 healthy subjects aged 3-20 y, from four Italian cities. There were 257 subjects 3-5 y old all residing in Southern Italy and 501 subjects 11-20 y old from both the South and North. The overall prevalence of non-immune subjects was 19.1%, without difference by sex. The rates of subjects lacking protective antibody titres was 25.3% in children 3-5 y old (all coming from South and the islands), 11.5% in those 11 y old, and 18.9% in the 18-20 y age-group, respectively. Subjects 11-20 y old residing in the South and the islands were more likely…

AdultMalePediatricsmedicine.medical_specialtyAdolescentTetanus immunizationTetanus.ImmunitymedicinePrevalenceTetanus ToxoidHumansChildHigh rateTetanusTetanusbusiness.industryPublic Health Environmental and Occupational HealthHealthy subjectsImmunityGeneral Medicinemedicine.diseaseAntibodies BacterialVaccinationItalyChild PreschoolFemaleProtective antibodyGeographical inequalitiesbusiness
researchProduct

Immunologic findings in workers formerly exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and its congeners

1998

One hundred ninety-two workers in a German pesticide factory who were exposed to polychlorinated dibenzodioxins and -furans (PCDD/PCDF) were investigated for former and present diseases and laboratory changes of the immune system. Moreover, in a subgroup of 29 highly exposed and 28 control persons, proliferation studies were performed. In addition to assays such as blood count, immunoglobulins, serum electrophoresis, monoclonal bands, surface markers, autoantibodies, and lymphocyte proliferation, two new methods, the rise of tetanus antibody concentration after vaccination and the in vitro resistance of lymphocytes to chromate, were used to diagnose the morphologic and functional state of t…

AdultMalePolychlorinated DibenzodioxinsHealth Toxicology and MutagenesisPolychlorinated dibenzodioxinsLymphocyte proliferationLymphocyte ActivationCohort Studieschemistry.chemical_compoundImmune systemImmunityOccupational ExposuremedicineChromatesTetanus ToxoidHumansPesticidesPhytohemagglutininsFuransAgedImmunity CellularbiologyTetanusPublic Health Environmental and Occupational HealthAutoantibodyMiddle Agedmedicine.diseaseVaccinationchemistryChemical IndustryImmunologyAntibody Formationbiology.proteinFemaleAntibodyResearch Article
researchProduct

Circadian variations in antigen-specific proliferation of human T lymphocytes and correlation to cortisol production.

1995

Cortisol is a well-known immunosuppressant when used therapeutically. The present investigation was set out to study if diurnal variations in endogenous cortisol production are reflected by changes in proliferative responses of human lymphocytes to either a mitogen (phytohemagglutinin-A, PHA) or an antigen (tetanus toxoid, TT) stimulus. The study included eight healthy volunteers. Blood was withdrawn at 0200, 0600, 1000, and 1800h for preparation of lymphocytes and determination of cortisol in plasma. Isolated cells were incubated without (baseline activity) or with inclusion of either 1 micrograms PHA or 10 micrograms TT. Proliferation was measured by labelling with 3H-thymidine for 16 h o…

AdultMalemedicine.medical_specialtyCellular immunityHydrocortisoneEndocrinology Diabetes and MetabolismT-LymphocytesEndogenyBiologyLymphocyte ActivationEndocrinologyImmune systemAntigenInternal medicinemedicineTetanus ToxoidHumansCircadian rhythmLymphocyte CountPhytohemagglutininsBiological PsychiatryHydrocortisoneEndocrine and Autonomic SystemsT lymphocyteCircadian RhythmPsychiatry and Mental healthEndocrinologyFemaleMitogensGlucocorticoidmedicine.drugPsychoneuroendocrinology
researchProduct

Antibody Induction Directed against the Tumor-Associated MUC4 Glycoprotein

2015

Mucin glycoproteins are important diagnostic and therapeutic targets for cancer treatment. Although several strategies have been developed to explore anti-tumor vaccines based on MUC1 glycopeptides, only few studies have focused on vaccines directed against the tumor-associated MUC4 glycoprotein. MUC4 is an important tumor marker overexpressed in lung cancer and uniquely expressed in pancreatic ductual adenocarcinoma. The aberrant glycosylation of MUC4 in tumor cells results in an exposure of its peptide backbone and the formation of tumor-associated glycopeptide antigens. Due to the low immunogenicity of these endogenous structures, their conjugation with immune stimulating peptide or prot…

Antibodies NeoplasmMolecular Sequence DataCancer VaccinesBiochemistryEpitopeEpitopesMiceAntigenAntibody SpecificityCell Line TumorTetanus ToxoidAnimalsHumansAmino Acid SequenceMolecular BiologyMUC1chemistry.chemical_classificationMice Inbred BALB CMucin-4biologyImmune SeraImmunogenicityVaccinationOrganic ChemistryToxoidGlycopeptidePancreatic NeoplasmschemistryTandem Repeat SequencesImmunologybiology.proteinMolecular MedicineFemalesense organsAntibodyGlycoproteinChemBioChem
researchProduct

Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen-Friedenreich Antigen and a Fluorine-Substituted An…

2010

Breast NeoplasmsCancer VaccinesAntibodiesCatalysisMiceCell Line TumorTetanus ToxoidmedicineAnimalsHumansAntigens Tumor-Associated CarbohydrateMUC1Vaccines SyntheticThomsen-Friedenreich AntigenChemistryTetanusMucin-1GlycopeptidesToxoidFluorineGeneral ChemistryFlow Cytometrymedicine.diseaseGlycopeptideBiochemistryFemaleConjugateAngewandte Chemie International Edition
researchProduct